Medicinal composition for treating psoriasis

Abstract

The invention provides a pharmaceutical composition for treating psoriasis, and its preparation forms include ointment and gel. The pharmaceutical composition contains 0.05%-0.5% (w / w) of tazarotene, 0.05%-2.5% (w / w) of adrenocorticosteroids and other pharmaceutically acceptable auxiliary agents. The adrenocortical hormone drug is preferably betamethasone dipropionate. The pharmaceutical composition of the invention has remarkable curative effect on psoriasis and good safety.

Description

Technical field: [0001] The invention relates to a pharmaceutical composition for treating psoriasis, in particular to an ointment and a gel containing tazarotene and adrenocortical hormone drugs. Background technique: [0002] Tazarotene and adrenal corticosteroids are commonly used in the clinical treatment of dyskeratotic skin diseases. Tazarotene can cut off the three pathological processes of such skin diseases: ① hyperplasia of keratinocytes in the basal layer; ② parakeratosis; ③ inflammatory response of the epidermis; In the early stage of inflammation, it can reduce exudation, edema, telangiectasia, leukocyte infiltration and phagocytosis, thereby improving symptoms such as redness, swelling, heat, and pain. In the later stage, it can inhibit the proliferation of capillaries and fibroblasts, continue the formation of granulation tissue, and prevent scarring Formation, reduce inflammation, corticosteroids and tazarotene combined treatment of psoriasis can shorten the...